

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山医药集团股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 00874)

OFFICIAL QUOTATION OF GP CORP. ON NEEQ

Reference is made to Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (the “**Company**”) (i) an announcement dated 19 December 2023 and a circular dated 5 January 2024 in relation to the proposed quotation of Guangzhou Pharmaceuticals Co., Ltd (“**GP Corp.**”), a subsidiary of the Company, on the National Equities Exchange and Quotations (the “**NEEQ**”); (ii) an announcement dated 17 June 2024 in relation to the confirmation from the Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) that the Company may proceed with the spin-off of GP Corp. by way of quotation on NEEQ pursuant to Practice Note 15 to the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (“**PN 15**”) and the grant of a waiver from strict compliance with the applicable requirements in relation to the assured entitlement under paragraph 3(f) of PN 15. GP Corp. has also submitted an application for quotation on NEEQ to the National Equities Exchange and Quotations Co., Ltd., which has been accepted; and (iii) an announcement dated 29 April 2025 in relation to the approval for the quotation of GP Corp. on NEEQ.

The board of directors of the Company (the “**Board**”) hereby announces that GP Corp. will be quoted and commence public trading on NEEQ from 20 May 2025, with the following quotation details:

Stock short name: GP Corp.*

Stock code: 874839

Method of transfer: collective bidding transfer

Level: innovation tier

The public transfer statement of GP Corp. has been disclosed on the designated information disclosure platform of NEEQ (www.neeq.com.cn or www.neeq.cc) on 29 April 2025 for investors’ reference.

The Board of

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 19 May 2025

As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Mr. Yang Jun, Ms. Cheng Ning and Mr. Li Hong as executive Directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive Directors.

* English translation denotes for identification purposes only